At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 148 enrolled
Drug / intervention
THERMOCOOL® SMARTTOUCH™ Catheterdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
THERMOCOOL® SMARTTOUCH™ Catheter for the Treatment of Symptomatic Paroxysmal Atrial Fibrillation Continued Access
In Brief
A Phase 3 clinical trial evaluating THERMOCOOL® SMARTTOUCH™ Catheter for Drug Refractory Symptomatic Paroxysmal Atrial Fibrillation. Completed, enrolled 148 participants across 20 sites.
Detailed Summary
This is a prospective, multicenter, non-randomized continued access clinical evaluation utilizing the THERMOCOOL® SMARTTOUCH™ catheter.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2012
First PostedJul 2012
Primary CompletionJun 2014
Study CompletionOct 2014
TodayJul 2026
First PostedJul 12, 2012
Enrollment StartJul 1, 2012
Primary CompletionJun 1, 2014
Study CompletionOct 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 14.0 years ago
Interventions
THERMOCOOL® SMARTTOUCH™ Catheterdevice
AF Ablation